Zynex Inc. $ZYXI Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Zynex Inc. (NASDAQ:ZYXI) by 19.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,317 shares of the company’s stock after buying an additional 8,661 shares during the period. Charles Schwab Investment Management Inc. owned about 0.17% of Zynex worth $115,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of America Corp DE increased its position in Zynex by 6.2% in the 4th quarter. Bank of America Corp DE now owns 24,114 shares of the company’s stock valued at $193,000 after acquiring an additional 1,407 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Zynex by 9.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 19,333 shares of the company’s stock worth $155,000 after acquiring an additional 1,660 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Zynex by 138.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,398 shares of the company’s stock worth $27,000 after acquiring an additional 1,975 shares during the period. Ameriprise Financial Inc. lifted its stake in Zynex by 2.1% in the 4th quarter. Ameriprise Financial Inc. now owns 96,813 shares of the company’s stock valued at $775,000 after buying an additional 1,993 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Zynex by 13.9% during the fourth quarter. Barclays PLC now owns 32,828 shares of the company’s stock worth $263,000 after buying an additional 4,007 shares in the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Analysts Set New Price Targets

ZYXI has been the topic of a number of recent analyst reports. LADENBURG THALM/SH SH raised Zynex from a “neutral” rating to a “buy” rating and set a $3.70 price target on the stock in a research note on Friday, August 1st. Royal Bank Of Canada cut their target price on Zynex from $4.00 to $3.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 15th. Finally, HC Wainwright downgraded shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Friday, August 1st. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.90.

Zynex Stock Performance

ZYXI opened at $1.49 on Friday. The stock has a market capitalization of $45.15 million, a PE ratio of -1.59 and a beta of 1.02. The firm’s fifty day moving average price is $1.99 and its 200 day moving average price is $2.76. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.62 and a quick ratio of 0.45. Zynex Inc. has a 12-month low of $1.23 and a 12-month high of $9.42.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.